📊

Executive Summary

Approved once-weekly long-acting growth hormone (SKYTROFA) for pediatric growth hormone deficiency, with label expansions into Turner syndrome, SGA, and additional growth disorders

SKYTROFA_TransCon_hGH

· TransCon prodrug

Approved

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy